Literature DB >> 17059640

Surveillance of sexually transmitted diseases in general practice: a description of trends in the Royal College of General Practitioners Weekly Returns Service between 1994 and 2001.

I Simms1, D M Fleming, C M Lowndes, G E Smith, R S Chapman.   

Abstract

This paper describes the incidence of sexually transmitted infections (STIs) recorded in the Weekly Returns Service (WRS) between 1994 and 2001. There were approximately 76,500 new diagnoses of STIs (7500 males, 71,000 females) and associated syndromes. Candidiasis was the commonest condition reported in males and females followed by pelvic inflammatory disease. The ratio of males to females was 7.1 for non-specific urethritis, and 9.1 and 2.1 for Reiter's syndrome and pediculosis pubis, respectively. The incidence of anogenital warts and genital herpes changed little over time. New diagnoses of genital herpes were higher in females than in males (ratio 2.8:1), whereas the mean annual incidence of genital warts was similar in males and females. The WRS provides an insight into the burden of STI diagnoses, and diagnoses related to STIs that are managed in general practice, and as such has the potential to make a substantial contribution to STI surveillance in England.

Entities:  

Mesh:

Year:  2006        PMID: 17059640     DOI: 10.1258/095646206780070992

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

1.  Management of first-episode pelvic inflammatory disease in primary care: results from a large UK primary care database.

Authors:  Amanda Nicholson; Greta Rait; Tarita Murray-Thomas; Gwenda Hughes; Catherine H Mercer; Jackie Cassell
Journal:  Br J Gen Pract       Date:  2010-10       Impact factor: 5.386

2.  Management of epididymo-orchitis in primary care: results from a large UK primary care database.

Authors:  Amanda Nicholson; Greta Rait; Tarita Murray-Thomas; Gwenda Hughes; Catherine H Mercer; Jackie Cassell
Journal:  Br J Gen Pract       Date:  2010-10       Impact factor: 5.386

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.